What Breast Cancer Does CDH1 Cause? Risk & MRI Guidelines
At a Glance
A CDH1 genetic mutation increases a woman's lifetime risk of developing lobular breast cancer to up to 52%. Because this type of cancer grows in a scattered pattern that is hard to see on standard mammograms, annual breast MRI screenings are recommended for CDH1 carriers starting at age 30.
In this answer
3 sections
Having a CDH1 mutation increases a woman’s lifetime risk of developing breast cancer to an estimated 39% to 52%, depending on family history, compared to the general population risk of about 13% [1][2][3]. (Note: This specific elevated breast cancer risk applies primarily to female carriers, not male carriers [4].) The CDH1 mutation specifically increases the risk of a type of breast cancer called Lobular Breast Cancer (LBC) [3][5]. Because of the unique way lobular breast cancer grows, standard yearly mammograms are often not enough to detect it early [6][7]. For this reason, specialized screening guidelines, including annual breast MRIs, are recommended for women with a CDH1 mutation [1].
What Type of Breast Cancer Does CDH1 Cause?
The CDH1 gene is responsible for producing a protein called E-cadherin, which acts like a “cellular glue” that holds cells together [8][9]. When there is a mutation in the CDH1 gene, this glue is missing [10][11].
Because the cells cannot stick together, lobular breast cancer does not typically form a distinct, hard lump [11][10]. Instead, it grows in a discohesive (scattered) pattern, with tumor cells spreading in single-file lines or thin strands through the breast tissue [11][10]. This growth pattern is biologically very similar to the way diffuse gastric cancer spreads in the stomach, which is why both are associated with the same genetic mutation [8].
Why Are Regular Mammograms Insufficient?
Standard 2D and even 3D mammograms (tomosynthesis) are excellent at detecting solid lumps or calcium deposits, which are common in other types of breast cancer. However, because lobular breast cancer grows in single-file lines and blends into the surrounding tissue without forming a hard lump, it is often “invisible” or very subtle on mammography [6][7][12].
Due to this hidden growth pattern, mammography alone has a lower detection rate for lobular breast cancer [6][13]. Medical experts recognize that supplemental imaging is necessary to confidently screen for and detect this specific type of cancer in its early stages [14][15]. While you may still receive an annual mammogram as part of your overall care plan, it should not be your only screening tool [16][17].
MRI Screening Guidelines for CDH1 Carriers
Because lobular breast cancer is harder to detect with standard methods, advanced imaging techniques like breast MRI (Magnetic Resonance Imaging) are required. Breast MRIs are highly sensitive and provide a much clearer picture of the breast tissue, making them far better at detecting lobular breast cancer than mammograms [18][19]. During a breast MRI, you typically lie face down while an IV contrast dye is used to help highlight any abnormal tissue.
The 2020 International Gastric Cancer Linkage Consortium (IGCLC) guidelines outline the standard of care for individuals with a CDH1 mutation. According to these guidelines:
- Annual breast MRIs are recommended for women with a pathogenic CDH1 variant [1][2].
- This MRI screening should begin at age 30 [1][17].
Your comprehensive breast surveillance will typically include the annual MRI alongside an annual mammogram and a clinical breast exam by your doctor [16][4].
Additional Risk Management Options
Beyond screening, your multidisciplinary care team may discuss other proactive ways to manage your risk. This can include chemoprevention (taking risk-reducing medications like tamoxifen or aromatase inhibitors) to lower the chance of developing breast cancer. While preventative removal of the breasts (prophylactic mastectomy) is generally not the standard recommendation for CDH1 carriers, it may be discussed depending on your personal risk tolerance and family history [4][1].
Common questions in this guide
What type of breast cancer does a CDH1 mutation cause?
Why aren't standard mammograms enough to detect lobular breast cancer?
At what age should women with a CDH1 mutation start getting breast MRIs?
What are my options for lowering my breast cancer risk if I have a CDH1 mutation?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.At what age should I begin my annual breast MRI screenings, based on my personal and family history?
- 2.Should I stagger my annual MRI and my annual mammogram every six months, or do them at the same time?
- 3.Does the imaging center have radiologists who are specifically experienced in looking for lobular breast cancer in high-risk patients?
- 4.Are risk-reducing medications (chemoprevention) an appropriate option for me to consider?
- 5.Who will coordinate my breast cancer screenings alongside my stomach cancer screenings to ensure nothing falls through the cracks?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (19)
- 1
Hereditary Diffuse Gastric Cancer Syndrome and the Role of CDH1: A Review.
Gamble LA, Heller T, Davis JL
JAMA surgery 2021; (156(4)):387-392 doi:10.1001/jamasurg.2020.6155.
PMID: 33404644 - 2
Hereditary Diffuse Gastric Cancer-Update Based on the Current Consort Recommendations.
Treese C, Siegmund B, Daum S
Current oncology (Toronto, Ont.) 2022; (29(4)):2454-2460 doi:10.3390/curroncol29040199.
PMID: 35448173 - 3
Germline CDH1 Variants and Lifetime Cancer Risk.
Ryan CE, Fasaye GA, Gallanis AF, et al.
JAMA 2024; (332(9)):722-729 doi:10.1001/jama.2024.10852.
PMID: 38873722 - 4
Multidisciplinary management of CDH1 germinal mutation and prophylactic management hereditary lobular breast cancer: A case report.
Mirandola S, Pellini F, Granuzzo E, et al.
International journal of surgery case reports 2019; (58()):92-95 doi:10.1016/j.ijscr.2019.03.053.
PMID: 31028995 - 5
First report of a Mexican family with mutation in the CDH1 gene.
Martínez Valenzuela C, Castelán-Maldonado EE, Carvajal-Zarrabal O, Calderón-Garcidueñas AL
Molecular genetics & genomic medicine 2020; (8(11)):e1208 doi:10.1002/mgg3.1208.
PMID: 32886433 - 6
Mammographically Occult Invasive Lobular Carcinoma With Intradermal Invasion.
Khanna S, Puckett Y
Cureus 2022; (14(7)):e27358 doi:10.7759/cureus.27358.
PMID: 36043018 - 7
A case of invasive lobular carcinoma, highlighting the emerging role of 18F-Fluoroestradiol PET.
Wallace M, Tavana A, Leon A, et al.
Radiology case reports 2025; (20(10)):5172-5177 doi:10.1016/j.radcr.2025.06.105.
PMID: 40761268 - 8
Prognosis and outcome in CDH1-mutant lobular breast cancer.
Corso G, Veronesi P, Sacchini V, Galimberti V
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 2018; (27(3)):237-238 doi:10.1097/CEJ.0000000000000405.
PMID: 29595757 - 9
CDH1 germline mutations and hereditary lobular breast cancer.
Corso G, Intra M, Trentin C, et al.
Familial cancer 2016; (15(2)):215-9 doi:10.1007/s10689-016-9869-5.
PMID: 26759166 - 10
Microenvironment-induced restoration of cohesive growth associated with focal activation of P-cadherin expression in lobular breast carcinoma metastatic to the colon.
Gronewold M, Grote I, Bartels S, et al.
The journal of pathology. Clinical research 2024; (10(2)):e12361 doi:10.1002/2056-4538.12361.
PMID: 38618992 - 11
Invasive Lobular Breast Cancer as a Distinct Disease: Implications for Therapeutic Strategy.
Luveta J, Parks RM, Heery DM, et al.
Oncology and therapy 2020; (8(1)):1-11 doi:10.1007/s40487-019-00105-0.
PMID: 32700069 - 12
Invasive lobular and ductal breast carcinoma differ in immune response, protein translation efficiency and metabolism.
Du T, Zhu L, Levine KM, et al.
Scientific reports 2018; (8(1)):7205 doi:10.1038/s41598-018-25357-0.
PMID: 29739984 - 13
ASO Author Reflections: Lobular Carcinoma of the Breast: Why Does the Incidence Continue to Rise?
Findlay-Shirras L, Arnaout A
Annals of surgical oncology 2020; (27(Suppl 3)):695-696 doi:10.1245/s10434-020-08984-8.
PMID: 32803549 - 14
Breast Radiologists' Perceptions on the Detection and Management of Invasive Lobular Carcinoma: Most Agree Imaging Beyond Mammography Is Warranted.
Coffey K, Berg WA, Dodelzon K, et al.
Journal of breast imaging 2024; (6(2)):157-165 doi:10.1093/jbi/wbad112.
PMID: 38340343 - 15
The Usefulness of Spectral Mammography in Surgical Planning of Breast Cancer Treatment-Analysis of 999 Patients with Primary Operable Breast Cancer.
Lorek A, Steinhof-Radwańska K, Barczyk-Gutkowska A, et al.
Current oncology (Toronto, Ont.) 2021; (28(4)):2548-2559 doi:10.3390/curroncol28040232.
PMID: 34287253 - 16
Hereditary lobular breast cancer with an emphasis on E-cadherin genetic defect.
Corso G, Figueiredo J, La Vecchia C, et al.
Journal of medical genetics 2018; (55(7)):431-441 doi:10.1136/jmedgenet-2018-105337.
PMID: 29929997 - 17
[Hereditary diffuse gastric cancer].
Knipper K, Fuchs HF, Alakus H, et al.
Chirurgie (Heidelberg, Germany) 2023; (94(5)):400-405 doi:10.1007/s00104-023-01806-z.
PMID: 36700973 - 18
Invasive Lobular Carcinoma: A Review of Imaging Modalities with Special Focus on Pathology Concordance.
Pereslucha AM, Wenger DM, Morris MF, Aydi ZB
Healthcare (Basel, Switzerland) 2023; (11(5)) doi:10.3390/healthcare11050746.
PMID: 36900751 - 19
Diagnostic Challenge of Invasive Lobular Carcinoma of the Breast: What Is the News? Breast Magnetic Resonance Imaging and Emerging Role of Contrast-Enhanced Spectral Mammography.
Costantini M, Montella RA, Fadda MP, et al.
Journal of personalized medicine 2022; (12(6)) doi:10.3390/jpm12060867.
PMID: 35743654
This page provides educational information about CDH1 mutations and breast cancer screening. Always consult a genetic counselor or high-risk breast specialist for personalized medical advice and screening plans.
Get notified when new evidence is published on Hereditary diffuse gastric cancer.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.